A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use Authors: Avia Merenlender Wagner, Itay Perlstein, Pavel Farkas, Michael Lamson, Pippa Loupe, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Kelli R. Franzenburg, Eran Harary, Anna Elgart Published: 2026 ABSTRACT BackgroundTV-46000 (Uzedy®) is a long-acting injectable antipsychotic for subcutaneous use that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension that was approved as a treatment for schizophrenia and bipolar I disorder by the US Food and Drug Administration (FDA) in April 2023 and October 2025, respectively. It is a risperidone injectable that can be administered once monthly or once every 2 months. As part of the clinical development of TV-46000, a Phase 1 open-label dose escalation study (TV46000-SAD-10055) was conducted to evaluate the safety and pharmacokinetics (PK) of TV-46000 in participants with schizophrenia or schizoaffective disorder.MethodsIndividuals diagnosed with schizophrenia or schizoaffective disorder were assigned to 1 of 8 cohorts, which consisted of single escalating doses (50 to 225 mg) or 3 multiple doses (75 mg or 150 mg) administered every month for 3 months. Every cohort was preceded by a run-in period of 7 days with daily oral risperidone (2–6 mg) followed by a 7-day washout period before the TV-46000 injection. TV-46000 was administered in the abdomen in all but one cohort, where 225 mg was administered in the upper arm, to assess interchangeability between injection sites. Outcome measures reported were adverse events (AEs), local tolerability, changes in neurological and clinical assessments, and PK measures (determined by risperidone and 9-OH risperidone total active moiety [TAM] concentrations).ResultsOf the 194 participants screened, 99 were included in the study. Of the 99 participants, 13 discontinued the study, but none of the discontinuations were related to the treatment. Most participants were Black or African American men, with a mean age of 44.2 years and a mean body mass index of 28.53 kg/m2. Treatment-emergent AEs after TV-46000 administration included injection-site reactions, increased blood creatine phosphokinase, and weight gain. There were two serious AEs; one death due to suicide and one exacerbation of schizophrenia requiring hospitalization that were both unrelated to TV-46000. After a single dose injection of TV-46000 50 to 225 mg, TAM concentrations reached clinically relevant plasma concentrations of 10 ng/mL within 24 hours for all doses and remained within therapeutic range for 28–56 days, depending on dose. The systemic exposure parameters (maximum, minimum, and average plasma concentration) after the third monthly TV-46000 injections of 75 and 150 mg were comparable with the corresponding steady-state exposure of 3–5-mg/day oral risperidone.ConclusionsOverall, TV-46000 was well tolerated with no new safety signals detected compared with other formulations of risperidone. The PK profile of TV-46000 exhibited favorable characteristics of an extended-release formulation, including rapid initial release for fast onset of action and prolonged systemic exposure adequate for monthly administration.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40263-026-01302-y. Key Points TV-46000 (Uzedy®), a long-acting injectable form of risperidone, was generally well tolerated in people with schizophrenia or schizoaffective disorder, with no new safety concerns compared with existing risperidone treatments.The medication reached helpful blood levels within a day and stayed in the therapeutic range for up to one to two months, supporting its use as a monthly or every-two-months option.These results suggest that TV-46000 may offer a convenient and reliable alternative for maintaining symptom control with fewer injections. TV-46000 (Uzedy®), a long-acting injectable form of risperidone, was generally well tolerated in people with schizophrenia or schizoaffective disorder, with no new safety concerns compared with existing risperidone treatments.The medication reached helpful blood levels within a day and stayed in the therapeutic range for up to one to two months, supporting its use as a monthly or every-two-months option.These results suggest that TV-46000 may offer a convenient and reliable alternative for maintaining symptom control with fewer injections. Introduction Schizophrenia is a chronic, debilitating mental disorder characterized by positive symptoms (e.g., delusions, hallucinations, and grossly disorganized or catatonic behavior), negative symptoms (e.g., affective flattening, alogia, and avolition), cognitive impairment, and motor dysfunctions [1]. It is estimated to affect about 0.6–1.9% of adults and 0.2% of adolescents [2–4]. Early and uninterrupted antipsychotic treatment is associated with improved symptomatic outcomes, which are important determinants of patient-centered outcomes in schizophrenia [5–7]. Long-term antipsychotic treatment is usually required for sustained remission [8]; however, suboptimal adherence and high discontinuation rates of oral antipsychotics are common and are risk factors for relapse [9, 10]. Long-acting injectable (LAI) antipsychotic agents have been associated with improved adherence, reductions in relapse and hospitalization rates, and lower discontinuation rates when compared with oral antipsychotics in people with schizophrenia [11–14]. Risperidone, a second-generation antipsychotic, was approved for the treatment of patients with schizophrenia in 1993. It is available in multiple LAI formulations, including intramuscular and subcutaneous (SC) products with differing release characteristics and dosing schedules [15, 16]. In addition, paliperidone, the major active metabolite of risperidone, is widely available as an intramuscular LAI and is commonly used in the treatment of schizophrenia [17]. TV-46000 (Uzedy®, Teva Neuroscience) is a risperidone long-acting SC antipsychotic with a once monthly (q1m) or once every two months (q2m) administration schedule and is US Food and Drug Administration (FDA) approved for the treatment of schizophrenia and bipolar I disorder in adults [18, 19]. The formulation contains risperidone suspended in dimethyl sulfoxide with two biodegradable copolymers. Unlike risperidone LAIs that employ pre-manufactured microspheres [15] or nanocrystal suspensions [16], TV-46000 is administered as a polymer solution that solidifies at the injection site [20]. The slow release of risperidone from the depot enables TV-46000 to be administered q1m at 50–125-mg risperidone or q2m at 100–250-mg risperidone for the treatment of patients with schizophrenia. The present study describes a Phase 1 clinical trial of TV-46000 in people with schizophrenia or schizoaffective disorder. Participants received either single or multiple ascending doses of TV-46000 to evaluate the safety, tolerability, and pharmacokinetics (PK) of TV-46000. Pharmacokinetic activity of both risperidone and its pharmacologically active metabolite, 9-hydroxyrisperidone (9-OH risperidone, paliperidone), was assessed as the total active moiety (TAM) because both molecules are considered to have a clinical effect [21]. The effect of site of administration (abdomen vs back of the upper arm) on TAM exposure using therapeutic dose levels of TV-46000 was also evaluated. Methods Study Design TV46000-SAD-10055 was a Phase 1, sequential, single-ascending, and multiple-dose study with an adaptive design to evaluate the safety, tolerability, and PK of TV-46000 for SC use in people with schizophrenia or schizoaffective disorder. The clinical trial consisted of a screening period (up to 26 days), an inpatient oral risperidone tolerability period (7 days) with washout (7 days), an inpatient and outpatient TV-46000 administration period (4 or 12 weeks), and a follow-up period (4 or 8 weeks). See Fig. 1 for more details on the study design.Fig. 1Overall study design of the Phase 1, open-label study of TV-46000. *Oral risperidone doses for the different cohorts were 2 mg/day for cohorts 1 and 2; 3 mg/day for cohorts 3 and 6; 4 mg/day for cohort 4; 5 mg/day for cohorts 7 and 8; and 6 mg/day for cohort 5, EoS end of study, PK pharmacokinetics Overall study design of the Phase 1, open-label study of TV-46000. *Oral risperidone doses for the different cohorts were 2 mg/day for cohorts 1 and 2; 3 mg/day for cohorts 3 and 6; 4 mg/day for cohort 4; 5 mg/day for cohorts 7 and 8; and 6 mg/day for cohort 5, EoS end of study, PK pharmacokinetics Ethics The clinical trial was conducted in accordance with the Good Clinical Practice guidelines and the ethical standards as laid down in the 1964 Declaration of Helsinki. The Schulman Associates IRB committee reviewed and approved the study (approval number IRB 201603437), and participants provided written consent. Participants Participants were males and females aged 18 to 55 years with a diagnosis of schizophrenia or schizoaffective disorder who met the following key inclusion criteria: clinically stable and not currently on antipsychotic treatment other than oral risperidone, eligible for risperidone treatment, body mass index (BMI) 18.0–35.0 kg/m2, a Positive and Negative Syndrome Scale (PANSS) score of ≤70, and a Clinical Global Impression–Severity of Illness (CGI-S) score of ≤3. Females had to be non-pregnant and were required to use birth control measures before and during the study and continue for one year after its completion. Treatments Oral Risperidone After randomization, participants received oral risperidone doses of 2–6 mg during the oral tolerability period. Every effort was made to ensure that oral risperidone was administered at daily doses that closely matched participants’ previously established stable regimens. TV-46000 Doses of TV-46000 and administration regimens were chosen on the basis of PK results from the first study in healthy volunteers (the RISPE1ZG15EU study, data on file Teva Pharmaceuticals); efforts were made to allocate participants to TV-46000 dose groups ranging from 50 mg to 225 mg that corresponded to their maintenance oral risperidone exposure. The study applied an adaptive dose-escalation design in which doses were adjusted according to the emerging PK and safety data reviewed by the safety review committee. TV-46000 was supplied as a ready-to-use white opaque injectable suspension in refrigerated single-use vials containing 30% wt/wt risperidone. Each syringe was prepared immediately before dosing and administered to all participants, preferably by the same medical technician at each site. Those who met the inclusion criteria were sequentially assigned to 1 of 8 treatment cohorts (for cohorts 1–7, TV-46000 was administered in the abdomen; for cohort 8, TV-46000 was administered in the back of the upper arm). Each cohort received daily oral doses of risperidone for 7 days followed by a 7-day washout period. Pharmacokinetic blood samples were collected multiple times up to 72 hours after the final dose of oral risperidone. After TV-46000 administration, PK blood samples were collected pre-dose and multiple times post-dose for 84 days for cohorts 1 and 2 and 112 days for cohorts 3, 4, 5, and 8. For cohorts 6 and 7, who received three consecutive doses of TV-46000, PK blood samples were collected pre-dose and multiple times after the first and second dose, and for 84 days after the third dose or early termination (Table S1). Safety assessments were conducted throughout the study. The safety review committee reviewed the cumulative PK and safety results and determined when to proceed to the next TV-46000 dose cohort. Safety Assessments and Outcomes Adverse event (AE) reporting, physical examinations including close inspections of injection sites, laboratory parameters, vital signs, 12-lead electrocardiogram (ECG), and pregnancy tests for females were conducted during the studies. Local tolerability was assessed with a visual analogue scale (VAS). Changes in neurological and clinical symptoms were assessed using the PANSS, Extrapyramidal Symptom Rating Scale, CGI-S, Columbia-Suicide Severity Rating Scale (C-SSRS), and Calgary Depression Scale for Schizophrenia scores/responses. Pharmacokinetic Measures Plasma concentrations of risperidone, 9-OH risperidone, and TAM were quantified using highly selective validated high performance liquid chromatography tandem-mass spectrometry. For detailed methods, see bioanalytical methods in the supplemental material. Total active moiety was defined as the sum of risperidone and 9-OH risperidone corrected by molecular weight, according to the following formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\left[ {{\mathrm{TAM}}} \right] \, = \, \left[ {{\mathrm{risperidone}}} \right] \, + \, \left[ {{9-}{\text{OH risperidone}}} \right] \cdot \left( {{41}0/{426}} \right).$$\end{document}TAM=risperidone+9-OH risperidone·410/426. Blood samples were collected in 2 mL dipotassium ethylenediaminetetraacetic acid tubes and immediately stored on ice and processed within 30 min of collection by centrifugation at 1500 g for 10 min at 5 °C. The resultant plasma was transferred into two appropriately labelled 2 mL screw-capped polypropylene cryovials, the primary tube contained ≥ 0.5 mL plasma. Samples were frozen within 60 min of collection and stored at minus 70 °C or below until they were shipped to Teva Pharmaceutical Works Private Ltd. Co. (Debrecen, Hungary) for the analysis of risperidone and its active metabolite, 9-OH risperidone. The plasma concentration versus time data for risperidone, 9-OH risperidone, and TAM were analyzed using Phoenix WinNonlin v6.3 (Certara USA, Inc., USA), while appropriate non-compartmental techniques generated and analyzed key PK parameters. The clinical effect, including safety and efficacy of risperidone, is thought to derive from both the parent molecule (risperidone) and its main active metabolite (9-OH risperidone) as TAM [22]. Therefore, TAM is considered the most clinically relevant assessment, and its PK parameters are presented herein and discussed. The PK parameters for TAM included the following: maximum (Cmax), minimal (Cmin), and average plasma drug concentration (Cavg), time to Cmax during a dosing interval (tmax), area under the plasma concentration-time curve (AUC) from time 0 to the end of the 28-day dosing interval (AUC0–28d), AUC from time 0 to last collected sample (AUC 0–t), AUC from time 0 extrapolated to infinity (AUC0–∞), and terminal half-life (t1/2). Accumulation ratio AUC is calculated as the ratio of AUC0–28d after the 3rd dose/AUC0–28d after the first dose, for the multiple dose cohorts 6 and 7. Accumulation ratio Cmax is the accumulation ratio calculated as the ratio of Cmax after the third dose/Cmax after the first dose for cohorts 6 and 7. Fluctuation of plasma concentrations was expressed as a percentage calculated as (Cmax–Cmin)/Cavg*100. Statistical Analyses Demographics (age, sex, race, ethnicity, weight at screening, height, and BMI) were summarized by cohort. All AEs, laboratory parameters, ECG reports, vital signs, and neurological and clinical symptoms were summarized using descriptive statistics for each cohort and for all participants unless otherwise noted. Plasma concentration data measured for risperidone, 9-OH risperidone, and TAM for each participant by cohort and nominal time point, were summarized using descriptive statistics. Concentration values that were below the limit of quantification (BLQ) were treated as 0, and missing values were ignored when calculating summary statistics for plasma concentrations. Concentration-time profiles for all individuals in the PK analysis set were used to calculate the plasma PK parameters for risperidone, 9-OH risperidone, and TAM with the BLQ values at time 0 (at a sampling time before the first quantifiable plasma concentration) or at a sampling time between two quantifiable concentrations, treated as 0. All other BLQ values were treated as missing. Actual sampling times were used in all computations involving sampling times. Summary statistics (i.e., mean, median, standard deviation [SD], coefficient of variation [CV%], range, and n) were calculated for all PK parameters plasma by cohort for risperidone, 9-OH risperidone, and TAM separately. Geometric mean and geometric CV% were presented for all PK parameters (except Tmax) by cohort for risperidone, 9-OH risperidone, and TAM. Results Participants Of the 194 participants screened, 99 met eligibility criteria, received at least one dose of study drug, and were evaluated for safety in the study. For cohorts 1–7, 12 participants were included in each cohort; and for cohort 8, 15 participants were included. Thirteen (13%) participants withdrew from the study, and the highest rate of withdrawal was in cohort 8 (n = 5). The reasons for withdrawal included withdrawal by the participant (n = 8), protocol violation (n = 2), lost to follow-up (n = 2), and one death. The individual who died during the study was in cohort 8; the death was considered not related to treatment (Fig. 2).Fig. 2Participant disposition for the Phase 1 open-label study of TV-46000. *Safety analysis set. **PK analysis set; four participants were excluded because of prohibited medication use. PK pharmacokinetics Participant disposition for the Phase 1 open-label study of TV-46000. *Safety analysis set. **PK analysis set; four participants were excluded because of prohibited medication use. PK pharmacokinetics Treatment cohorts were well matched for demographic and clinical characteristics (Table 1). Most participants were men (81%) and were Black or African American (96%); mean (range) age was 44.2 years (20–56 years), weight 86.9 kg (57.8–113.4 kg), and BMI 28.53 kg/m2 (19.6–34.8 kg/m2). There were no clinically significant findings regarding the medical history of the participants, and the eight cohorts were comparable in their use of prior and concomitant medications. Table 1Demographics and clinical characteristics of participants overall and for each treatment cohortCharacteristicCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 8OverallDosing regimen50 mg(n=12)75 mg(n=12)100 mg(n=12)150 mg(n=12)225 mg(n=12)75 mg(n=12)150 mg(n=12)225 mg(n=15)(n=99)Sex, male, n (%)11 (92)8 (67)9 (75)10 (83)9 (75)12 (100)9 (75)12 (80)80 (81)Race, n (%)Black or African American12 (100)12 (100)12 (100)12 (100)10 (83)12 (100)12 (100)13 (87)95 (96)White00002 (17)002 (13)4 (4)Ethnicity, n (%)Hispanic or Latino0001 (8)1 (8)1 (8)1 (8)2 (13)6 (6)Not Hispanic or Latino12 (100)12 (100)12 (100)11 (92)11 (92)10 (83)11 (92)13 (87)92 (93)Unknown000001 (8)001 (1)Age, years, mean (SD), [range]46.5 (7.03) [33–55]49.0 (4.95) [37–54]45.3 (7.81) [28–53]44.0 (7.15) [30–52]43.9 (8.98) [28–55]42.4 (9.42) [29–53]40.6 (11.29) [20–55]42.3 (11.49) [25–56]44.2 (8.90) [20–56]Screening weight, kg, mean (SD), [range]86.88 (16.00) [57.8–111.4]89.14 (17.40) [62.4–112.3]85.55 (19.42) [58.2–112.2]80.43 (11.35) [59.3–98.1]90.10 (14.02) [67.2–111.2]87.75 (12.99) [64.4–110.2]87.47 (20.02) [58.8–113.4]87.62 (10.01) [73.2–104.6]86.89 (15.08) [57.8–113.4]Height, cm, mean (SD), [range]175.79 (6.57) [164.5–188.0]170.73 (9.00) [153.0–188.0]175.57 (9.88) [152.4–189.0]172.13 (8.55) [158.0–184.1]173.00 (8.75) [157.0–185.0]177.51 (5.71) [169.0–189.0]175.47 (7.72) [162.0–185.2]175.09 (7.20) [157.2–183.0]174.43 (7.99)[152.4–189.0]BMI, kg/m2, mean (SD) [range]28.09 (4.93) [21.2–33.7]30.34 (3.85) [22.9–34.5]27.54 (4.60) [19.6–33.9]27.33 (4.68) [20.0–32.4]30.09 (3.84) [20.3–34.2]27.88 (4.11) [20.6–33.8]28.18 (5.11) [20.5–34.8]28.74 (4.22) [22.5–34.5]28.53 (4.40) [19.6–34.8]BMI body mass index, SD standard deviation Table 1Demographics and clinical characteristics of participants overall and for each treatment cohortCharacteristicCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Cohort 7Cohort 8OverallDosing regimen50 mg(n=12)75 mg(n=12)100 mg(n=12)150 mg(n=12)225 mg(n=12)75 mg(n=12)150 mg(n=12)225 mg(n=15)(n=99)Sex, male, n (%)11 (92)8 (67)9 (75)10 (83)9 (75)12 (100)9 (75)12 (80)80 (81)Race, n (%)Black or African American12 (100)12 (100)12 (100)12 (100)10 (83)12 (100)12 (100)13 (87)95 (96)White00002 (17)002 (13)4 (4)Ethnicity, n (%)Hispanic or Latino0001 (8)1 (8)1 (8)1 (8)2 (13)6 (6)Not Hispanic or Latino12 (100)12 (100)12 (100)11 (92)11 (92)10 (83)11 (92)13 (87)92 (93)Unknown000001 (8)001 (1)Age, years, mean (SD), [range]46.5 (7.03) [33–55]49.0 (4.95) [37–54]45.3 (7.81) [28–53]44.0 (7.15) [30–52]43.9 (8.98) [28–55]42.4 (9.42) [29–53]40.6 (11.29) [20–55]42.3 (11.49) [25–56]44.2 (8.90) [20–56]Screening weight, kg, mean (SD), [range]86.88 (16.00) [57.8–111.4]89.14 (17.40) [62.4–112.3]85.55 (19.42) [58.2–112.2]80.43 (11.35) [59.3–98.1]90.10 (14.02) [67.2–111.2]87.75 (12.99) [64.4–110.2]87.47 (20.02) [58.8–113.4]87.62 (10.01) [73.2–104.6]86.89 (15.08) [57.8–113.4]Height, cm, mean (SD), [range]175.79 (6.57) [164.5–188.0]170.73 (9.00) [153.0–188.0]175.57 (9.88) [152.4–189.0]172.13 (8.55) [158.0–184.1]173.00 (8.75) [157.0–185.0]177.51 (5.71) [169.0–189.0]175.47 (7.72) [162.0–185.2]175.09 (7.20) [157.2–183.0]174.43 (7.99)[152.4–189.0]BMI, kg/m2, mean (SD) [range]28.09 (4.93) [21.2–33.7]30.34 (3.85) [22.9–34.5]27.54 (4.60) [19.6–33.9]27.33 (4.68) [20.0–32.4]30.09 (3.84) [20.3–34.2]27.88 (4.11) [20.6–33.8]28.18 (5.11) [20.5–34.8]28.74 (4.22) [22.5–34.5]28.53 (4.40) [19.6–34.8]BMI body mass index, SD standard deviation Demographics and clinical characteristics of participants overall and for each treatment cohort 50 mg (n=12) 75 mg (n=12) 100 mg (n=12) 150 mg (n=12) 225 mg (n=12) 75 mg (n=12) 150 mg (n=12) 225 mg (n=15) 174.43 (7.99) [152.4–189.0] BMI body mass index, SD standard deviation Safety Assessments in Participants with Schizophrenia or Schizoaffective Disorder Adverse events occurring in ≥5% of participants for the safety population for oral risperidone (n = 99) were headache (n = 6; 6%), insomnia (n = 7; 7%), sedation (n = 30; 30%), and tachycardia (n = 7; 7%). Adverse events occurring in ≥5% of participants for the safety population for TV-46000 (n = 99) were blood creatine phosphokinase increases (n = 7; 7%), dry mouth (n = 5; 5%), auditory hallucinations (n = 6; 6%), headache (n = 8; 8%), injection-site erythema (n = 10; 10%), injection-site induration (n = 5; 5%), injection-site pain (n = 10; 10%), injection-site pruritus (n = 11; 11%), injection-site swelling (n = 7; 7%), insomnia (n = 9; 9%), sedation (n = 8; 8%), upper respiratory tract infection (n = 5; 5%), and weight gain (n = 34; 34%). Most AEs reported by the TV-46000-injected groups were mild in intensity (n = 59; 60% of participants). A complete list of reported AEs by cohort (occurring in ≥5% of participants) is shown in Table S2. Across the five TV-46000 single-dose cohorts, the percentage of participants reporting at least 1 AE ranged from 5 individuals (42%) in cohort 4 (150 mg) to 12 individuals (100%) in cohort 5 (225 mg), respectively. There were two serious AEs (SAEs) that occurred during the study. One was a completed suicide by a participant and the other an exacerbation of schizophrenia, both in cohort 8. The investigators and sponsor did not consider either SAE to be related to oral risperidone or TV-46000. The most frequently reported (≥5% of participants) treatment-emergent AEs were weight gain, injection-site reactions, insomnia, sedation, headache, increased blood creatine phosphokinase, and auditory hallucinations. For the clinical and neurological symptom assessments, changes from baseline in PANSS total scores and mean extrapyramidal symptom rating scale (ESRS) scores did not reveal any clinically meaningful trends for TV-46000 and/or oral risperidone. The CGI-S scores remained at 3 (mildly ill) throughout the study and C-SSRS and CDSS also revealed no symptoms or mild symptoms with no new safety signals for TV-46000. Local tolerability as assessed by mean VAS scores for injection-site pain were 3.5 or lower on a 10-point scale (where 0 represents no pain or sensation, 1–3 mild pain or sensation, 4–6 moderate pain or sensation, and 7–10 severe pain or sensation) immediately after dosing; scores decreased notably within 10 minutes of dosing. The VAS scores were collected until no pain was reported by each participant. Injection-site reactions were generally mild or moderate in severity and transient in nature. Clinical laboratory tests (including clinical chemistry, hematology, and urinalysis), ECG, vital signs, and physical examination did not reveal any clinically meaningful trends in mean changes from baseline or clinically significant findings in any of these assessments for TV-46000 and/or oral risperidone. Consistent with other risperidone formulations, mean prolactin levels increased from baseline after oral risperidone and single and multiple doses of TV-46000. Pharmacokinetics Oral Risperidone Under steady-state conditions after oral risperidone administration on Days 1–7, the TAM tmax values ranged from 1.5 to 2 hours across all doses 2–6 mg/day. Systemic exposure of TAM increased in a dose-linear fashion for doses of 2–5 mg/day. The exposure level for 6-mg/day dose was less than proportional compared with the lower doses. The TAM half-lives ranged from 23.4 to 27.1 hours across all dose levels. The fluctuation between peak and trough plasma concentrations at steady state ranged from 121% to 158% across the 2- to 6-mg/day dose range. TV-46000 Single doses Participants in cohorts 1–5 and cohort 8 were administered single doses of TV-46000. After single SC injections, TV-46000 PK profiles were qualitatively similar across doses with each demonstrating a rapid initial absorption phase, a slower secondary absorption phase, and a steady decline in TAM concentration from about Day 20 (Fig. 3). Total active moiety concentrations reached therapeutic levels (≥ 10 ng/mL) [23] within 6–24 hours after injection and were maintained for 28 to 56 days, depending on dose. TV-46000 demonstrated linear PK exposure; TAM exposures (based on Cmax and AUC) increased proportionally with increasing dose over the range tested in the study. As shown in Table 2, mean t1/2 values for TAM ranged from 15 to 21 days.Fig. 3.Mean (± SE) plasma TAM concentrations (ng/mL) after TV-46000 single SC doses. Cohorts 1, 2, 3, 4, 5, and 8 received 50, 75, 100, 150, 225, and 225 mg TV-46000, respectively. Cohorts 1, 2, 3, 4, and 5 received the injection in the abdomen and cohort 8 in the back of the upper arm. The dashed line indicates the TAM concentration reference value (10 ng/mL) for the lowest therapeutic dose. SC subcutaneous, SE standard error, TAM total active moietyTable 2Total active moiety PK parameters by treatment cohort after a single SC dose of TV-46000PK parameter (units)aCohort 1(50 mg, n=12)AbdomenCohort 2(75 mg, n=12)AbdomenCohort 3(100 mg, n=12)AbdomenCohort 4(150 mg, n=12)AbdomenCohort 5(225 mg, n=12)AbdomenCohort 8(225 mg, n=15)Back of the upper armtmax, daysa10.5 (3.0–24.0)8.0 (2.0–21.1)10 (0.5–35.0)14.0 (4.0–28.0)b11 (6–20.0)14.0 (1.0–24.0)cCmax, ng/mL17.6 (49.0)21.5 (36.2)30.7 (43.0)39.6 (39.8)b53.9 (55.6)69.3 (50.2)cC28d, ng/mL7.9 (50.8)8.9 (48.7)16.0 (30.5)20.1 (39.8)28.2 (38.8)35.6 (70.4)cC56d, ng/mLNANA5.42 (61.1)5.3 (68.1)8.1 (63.8)4.1 (79.2)dAUC0–t, ng.h/mL11,990.3 (36.9)14,442.9 (42.1)26,085.3 (21.4)27,722.7 (29.6)b45,195.1 (28.8)42,082.5 (44.3)cAUC0–∞, ng.h/mL15,797.5 (26.3)f15,356.2 (28.0)e27,352.4 (23.0)b30,475.9 (28.5)f47,524.9 (25.4)f55,499.0 (32.8)bt1/2, daysa16.2 (8.9)f21.3 (11.4)e19.8 (14.4)b17.8 (7.8)f14.8 (5.3)f19.7 (11.8)bAUC0–∞ area under the plasma concentration-time curve from time 0 to infinity, AUC0–t area under the plasma concentration time curve from time 0 to the last measurable concentration, C28d observed plasma concentration on Day 28, C56d observed plasma concentration on Day 56, Cmax maximum plasma drug concentration, CV% coefficient of variation, NA not applicable, PK pharmacokinetics, SC subcutaneous, SD standard deviation, t1/2 terminal half-life, TAM total active moiety, tmax time to Cmax during a dosing intervalaAll parameters presented as geometric mean (CV%), except for tmax, which is presented as median (range), and t1/2, which is presented as mean (SD); bn=10; cn=13; dn=11; fn=7; en=9 Mean (± SE) plasma TAM concentrations (ng/mL) after TV-46000 single SC doses. Cohorts 1, 2, 3, 4, 5, and 8 received 50, 75, 100, 150, 225, and 225 mg TV-46000, respectively. Cohorts 1, 2, 3, 4, and 5 received the injection in the abdomen and cohort 8 in the back of the upper arm. The dashed line indicates the TAM concentration reference value (10 ng/mL) for the lowest therapeutic dose. SC subcutaneous, SE standard error, TAM total active moiety Table 2Total active moiety PK parameters by treatment cohort after a single SC dose of TV-46000PK parameter (units)aCohort 1(50 mg, n=12)AbdomenCohort 2(75 mg, n=12)AbdomenCohort 3(100 mg, n=12)AbdomenCohort 4(150 mg, n=12)AbdomenCohort 5(225 mg, n=12)AbdomenCohort 8(225 mg, n=15)Back of the upper armtmax, daysa10.5 (3.0–24.0)8.0 (2.0–21.1)10 (0.5–35.0)14.0 (4.0–28.0)b11 (6–20.0)14.0 (1.0–24.0)cCmax, ng/mL17.6 (49.0)21.5 (36.2)30.7 (43.0)39.6 (39.8)b53.9 (55.6)69.3 (50.2)cC28d, ng/mL7.9 (50.8)8.9 (48.7)16.0 (30.5)20.1 (39.8)28.2 (38.8)35.6 (70.4)cC56d, ng/mLNANA5.42 (61.1)5.3 (68.1)8.1 (63.8)4.1 (79.2)dAUC0–t, ng.h/mL11,990.3 (36.9)14,442.9 (42.1)26,085.3 (21.4)27,722.7 (29.6)b45,195.1 (28.8)42,082.5 (44.3)cAUC0–∞, ng.h/mL15,797.5 (26.3)f15,356.2 (28.0)e27,352.4 (23.0)b30,475.9 (28.5)f47,524.9 (25.4)f55,499.0 (32.8)bt1/2, daysa16.2 (8.9)f21.3 (11.4)e19.8 (14.4)b17.8 (7.8)f14.8 (5.3)f19.7 (11.8)bAUC0–∞ area under the plasma concentration-time curve from time 0 to infinity, AUC0–t area under the plasma concentration time curve from time 0 to the last measurable concentration, C28d observed plasma concentration on Day 28, C56d observed plasma concentration on Day 56, Cmax maximum plasma drug concentration, CV% coefficient of variation, NA not applicable, PK pharmacokinetics, SC subcutaneous, SD standard deviation, t1/2 terminal half-life, TAM total active moiety, tmax time to Cmax during a dosing intervalaAll parameters presented as geometric mean (CV%), except for tmax, which is presented as median (range), and t1/2, which is presented as mean (SD); bn=10; cn=13; dn=11; fn=7; en=9 Total active moiety PK parameters by treatment cohort after a single SC dose of TV-46000 AUC0–∞ area under the plasma concentration-time curve from time 0 to infinity, AUC0–t area under the plasma concentration time curve from time 0 to the last measurable concentration, C28d observed plasma concentration on Day 28, C56d observed plasma concentration on Day 56, Cmax maximum plasma drug concentration, CV% coefficient of variation, NA not applicable, PK pharmacokinetics, SC subcutaneous, SD standard deviation, t1/2 terminal half-life, TAM total active moiety, tmax time to Cmax during a dosing interval aAll parameters presented as geometric mean (CV%), except for tmax, which is presented as median (range), and t1/2, which is presented as mean (SD); bn=10; cn=13; dn=11; fn=7; en=9 Injection-site interchangeability Participants in cohorts 5 and 8 each received a single SC injection of 225-mg TV-46000 in the abdomen (similar to cohorts 1 to 4) or back of the upper arm, respectively. Administration into either the abdomen or back of the upper arm resulted in similar AUC0–∞ parameters (Table S3). Geometric mean ratios for Cmax and the observed plasma concentration on Day 28 suggested approximately 30% higher exposures after SC injection into the back of the upper arm than SC injection into the abdomen (Table S3). However, considering the interparticipant variability, the overall exposure was comparable between the two cohorts. Multiple doses Participants in cohort 6 and 7 were administered multiple doses of TV-46000. Similar to the single-dose administration, after each of the three monthly injections, plasma TAM concentrations increased rapidly, and the peak was followed by a slow decline until the last sample collection on Day 140 ± 2 (Fig. 4).Fig. 4.Mean (±SE) TAM plasma concentrations after three once-monthly injections of TV-46000 from multiple-dose cohorts 6 and 7 (75 mg and 150 mg). (a) Mean (±SE) TAM plasma concentrations after three once-monthly injections of TV-46000. (b) Mean (±SE) TAM plasma concentrations in log scale after the third monthly injection of TV-46000 from multiple-dose cohorts (75 mg and 150 mg). The dashed line indicates the TAM concentration reference value (10 ng/mL) for the lowest therapeutic dose. SE standard error, TAM total active moiety Mean (±SE) TAM plasma concentrations after three once-monthly injections of TV-46000 from multiple-dose cohorts 6 and 7 (75 mg and 150 mg). (a) Mean (±SE) TAM plasma concentrations after three once-monthly injections of TV-46000. (b) Mean (±SE) TAM plasma concentrations in log scale after the third monthly injection of TV-46000 from multiple-dose cohorts (75 mg and 150 mg). The dashed line indicates the TAM concentration reference value (10 ng/mL) for the lowest therapeutic dose. SE standard error, TAM total active moiety The Tmax median values ranged from 7.5 to 15.5 days and were similar to those observed after a single SC administration of 75-mg and 150-mg TV-46000. Total active moiety exposure (Cmax and AUC) appeared to increase in a proportional manner across the doses tested in the study (Table 3). Geometric mean accumulation ratios for AUC, defined as the ratio of AUC0–28d after the third dose/AUC0–28d after the first dose, were 1.58 and 1.81 for the 75-mg and 150-mg dose groups, respectively. Geometric mean accumulation ratios for Cmax were 1.57 and 1.75 for the 75-mg and 150-mg dose groups, respectively. Table 3Total active moiety PK parameters by treatment cohort after third dose of TV-46000PK parameter(units) on Day 57 administration timeaCohort 6(75 mg, n=12)Cohort 7(150 mg, n=12)tmax, daysa7.5 (1.3–14.0)9.0 (1.0–21.0)Cmax, ng/mL33.9 (23.9)69.6 (44.2)AUC0–t, ng.h/mL23,855 (25.2)60,118 (40.1)AUC0–∞, ng.h/mL25,596 (25.1)67,193 (45.3)AUC0–28d, ng.h/mL15,146 (18.8)32,918 (39.7)t1/2, daysa19.3 (7.4)22.2 (10.9)AUC0–∞ area under the plasma concentration-time curve from time 0 to infinity, AUC0–t area under the plasma concentration time curve from time 0 to the last measurable concentration, AUC0–28d area under the plasma concentration time curve from time 0 to the end of the 28-day dosing interval, Cmax maximum plasma drug concentration, CV%, coefficient of variation, PK pharmacokinetics, SD standard deviation, t1/2 terminal half-life, TAM total active moiety, tmax time to Cmax during a dosing intervalaAll parameters presented as geometric mean (CV%), except for tmax, which is presented as median (range), and t1/2, which is presented as mean (SD) Table 3Total active moiety PK parameters by treatment cohort after third dose of TV-46000PK parameter(units) on Day 57 administration timeaCohort 6(75 mg, n=12)Cohort 7(150 mg, n=12)tmax, daysa7.5 (1.3–14.0)9.0 (1.0–21.0)Cmax, ng/mL33.9 (23.9)69.6 (44.2)AUC0–t, ng.h/mL23,855 (25.2)60,118 (40.1)AUC0–∞, ng.h/mL25,596 (25.1)67,193 (45.3)AUC0–28d, ng.h/mL15,146 (18.8)32,918 (39.7)t1/2, daysa19.3 (7.4)22.2 (10.9)AUC0–∞ area under the plasma concentration-time curve from time 0 to infinity, AUC0–t area under the plasma concentration time curve from time 0 to the last measurable concentration, AUC0–28d area under the plasma concentration time curve from time 0 to the end of the 28-day dosing interval, Cmax maximum plasma drug concentration, CV%, coefficient of variation, PK pharmacokinetics, SD standard deviation, t1/2 terminal half-life, TAM total active moiety, tmax time to Cmax during a dosing intervalaAll parameters presented as geometric mean (CV%), except for tmax, which is presented as median (range), and t1/2, which is presented as mean (SD) Total active moiety PK parameters by treatment cohort after third dose of TV-46000 AUC0–∞ area under the plasma concentration-time curve from time 0 to infinity, AUC0–t area under the plasma concentration time curve from time 0 to the last measurable concentration, AUC0–28d area under the plasma concentration time curve from time 0 to the end of the 28-day dosing interval, Cmax maximum plasma drug concentration, CV%, coefficient of variation, PK pharmacokinetics, SD standard deviation, t1/2 terminal half-life, TAM total active moiety, tmax time to Cmax during a dosing interval aAll parameters presented as geometric mean (CV%), except for tmax, which is presented as median (range), and t1/2, which is presented as mean (SD) Total active moiety exposure parameters (Cmax, Cmin, and Cavg) after the third monthly TV-46000 injections of 75 mg and 150 mg were comparable with the values of these parameters after oral risperidone 3 mg and 5 mg at steady state, respectively (Table 4). The percent fluctuation, a variable characterizing the difference between peak and trough concentrations, was 168% and 137% after the third administration of TV-46000 injections of 75 mg and 150 mg, whereas oral risperidone dose fluctuations ranged from 132% to 128%. After the third TV-46000 dose of 75 mg or 150 mg every 28 days, Cmax and AUC0–28d increased by 60% to 80% relative to the first dose. After 3 consecutive monthly doses, systemic exposure (geometric mean of Cmax, and AUC0–28d) appeared to be approaching a plateau for the 75-mg dose group but not for the 150-mg dose group (Table 5). Table 4Total active moiety PK parameters for oral risperidone and the third dose of TV-46000 PK parameter (units)a Steady state oral dose TV-46000 third dose 3 mg 5 mg 75 mg 150 mg Cmax, ng/mLb 39.8 (27.3) 62.2 (36.3) 33.9 (23.9) 69.6 (44.2) Cmin, mean, ng/mLc 11.86 (37.2) 18.8 (56.1) 15.1 (43.4) 37.6 (36.3) Cavg, mean, ng/mLd 20.7 (30.2) 31.9 (41.6) 18.7 (30.0) 40.1 (39.7) Fluctuation, mean,%e 132 (25.5) 128 (40.9) 168 (42.9) 137 (50.9) Cavg average plasma drug concentration, Cmax maximum plasma drug concentration, Cmin minimum plasma drug concentration, CV% coefficient of variation, PK pharmacokinetics, TAM total active moiety aAll parameters presented as geometric mean (CV%) bCmax for oral risperidone and Cmax57d for third dose of TV-46000 cC24h for oral risperidone and C84d for third dose of TV-46000 dCavg24h for oral risperidone and Cavg57d for third dose of TV-46000 eFluctuation of plasma concentrations expressed as a percentage (%Fluctuation), calculated as (Cmax–Cmin)/Cavg*100 Table 5Total active moiety PK parameters on Days 1, 29, and 57 after administration of TV-46000PK parameter (units)aCohort 6(75 mg, n=12)Cohort 7(150 mg, n=12)Day 1Day 29Day 57Day 1Day 29Day 57Cmax, ng/mL21.331.733.939.254.869.6AUC0–28d, h*ng/mL9,54013,95415,14618,19026,03132,918AUC0–28d area under the plasma concentration time curve from time 0 to the end of the 28-day dosing interval, Cmax maximum plasma drug concentration, PK pharmacokinetics, TAM total active moietyaAll parameters are presented as geometric mean Table 4Total active moiety PK parameters for oral risperidone and the third dose of TV-46000 PK parameter (units)a Steady state oral dose TV-46000 third dose 3 mg 5 mg 75 mg 150 mg Cmax, ng/mLb 39.8 (27.3) 62.2 (36.3) 33.9 (23.9) 69.6 (44.2) Cmin, mean, ng/mLc 11.86 (37.2) 18.8 (56.1) 15.1 (43.4) 37.6 (36.3) Cavg, mean, ng/mLd 20.7 (30.2) 31.9 (41.6) 18.7 (30.0) 40.1 (39.7) Fluctuation, mean,%e 132 (25.5) 128 (40.9) 168 (42.9) 137 (50.9) Cavg average plasma drug concentration, Cmax maximum plasma drug concentration, Cmin minimum plasma drug concentration, CV% coefficient of variation, PK pharmacokinetics, TAM total active moiety aAll parameters presented as geometric mean (CV%) bCmax for oral risperidone and Cmax57d for third dose of TV-46000 cC24h for oral risperidone and C84d for third dose of TV-46000 dCavg24h for oral risperidone and Cavg57d for third dose of TV-46000 eFluctuation of plasma concentrations expressed as a percentage (%Fluctuation), calculated as (Cmax–Cmin)/Cavg*100 Total active moiety PK parameters for oral risperidone and the third dose of TV-46000 Cavg average plasma drug concentration, Cmax maximum plasma drug concentration, Cmin minimum plasma drug concentration, CV% coefficient of variation, PK pharmacokinetics, TAM total active moiety aAll parameters presented as geometric mean (CV%) bCmax for oral risperidone and Cmax57d for third dose of TV-46000 cC24h for oral risperidone and C84d for third dose of TV-46000 dCavg24h for oral risperidone and Cavg57d for third dose of TV-46000 eFluctuation of plasma concentrations expressed as a percentage (%Fluctuation), calculated as (Cmax–Cmin)/Cavg*100 Table 5Total active moiety PK parameters on Days 1, 29, and 57 after administration of TV-46000PK parameter (units)aCohort 6(75 mg, n=12)Cohort 7(150 mg, n=12)Day 1Day 29Day 57Day 1Day 29Day 57Cmax, ng/mL21.331.733.939.254.869.6AUC0–28d, h*ng/mL9,54013,95415,14618,19026,03132,918AUC0–28d area under the plasma concentration time curve from time 0 to the end of the 28-day dosing interval, Cmax maximum plasma drug concentration, PK pharmacokinetics, TAM total active moietyaAll parameters are presented as geometric mean Total active moiety PK parameters on Days 1, 29, and 57 after administration of TV-46000 AUC0–28d area under the plasma concentration time curve from time 0 to the end of the 28-day dosing interval, Cmax maximum plasma drug concentration, PK pharmacokinetics, TAM total active moiety aAll parameters are presented as geometric mean Discussion This Phase 1 open-label study evaluated the safety, tolerability, and PK of single-ascending doses and multiple doses of TV-46000 for use in individuals with schizophrenia or schizoaffective disorder. TV-46000 achieved and maintained clinically relevant levels of risperidone rapidly within 6 to 24 hours after injection. Because participants entered the dosing phase following an oral risperidone washout period, baseline risperidone concentrations were minimal, representing a conservative exposure scenario. The rapid attainment of clinically relevant TAM concentrations within 24 hours therefore supports the formulation’s ability to achieve therapeutic exposure without oral supplementation. The mean half-life ranged between 14.4 and 20.6 days and was maintained above the therapeutic threshold of 10 ng/mL for a duration of 28 to 56 days, depending on the administered dose. The absence of a burst effect or uncontrolled release further underscored the formulation’s reliability in achieving consistent drug delivery. TV-46000 demonstrated a PK profile characterized by flip-flop kinetics [22], wherein the rate of systemic absorption is slower than the rate of elimination. This rate resulted in a prolonged absorption phase that governs the drug’s apparent terminal half-life. Such a profile is particularly advantageous in the context of schizophrenia treatment as it facilitates sustained therapeutic plasma concentrations over the dosing interval. This sustained release is indicative of a favorable PK profile characterized by linear exposure with increasing doses from 50 mg to 225 mg, aligning with findings from previous studies on LAI antipsychotics that emphasize the importance of maintaining therapeutic levels over extended periods [21, 24]. This dose proportionality is crucial for predicting the therapeutic effects of TV-46000 across a range of doses and ensuring consistency in patient outcomes. Results indicated that after three consecutive monthly doses, TAM exposure parameters approached a plateau for participants who received the 75-mg TV-46000 dose, while the participants who received 150 mg TV-46000 continued to show an increase, consistent with the expected PK behavior of an extended-release formulation administered at monthly intervals. This gradual accumulation of drug concentration is essential for ensuring optimal therapeutic effects while minimizing the risk of side effects associated with peak plasma levels [25]. Accumulation is anticipated until steady state is achieved. Based on the observed accumulation ratios in this study and comparison with steady-state oral risperidone, systemic exposure remained within the exposure range associated with 3- to 5-mg/day oral risperidone and did not exceed established therapeutic levels. Although percentage fluctuation values were higher for TV-46000 (137% to 168%) than for oral risperidone (128% to 132%), fluctuation for TV-46000 reflects peak-to-trough variation across a 28-day dosing interval, whereas fluctuation for oral risperidone reflects variation over a 24-hour dosing interval. Therefore, these values are not directly comparable. Importantly, Cmin and Cavg values after multiple TV-46000 doses remained within the therapeutic range and were comparable to those observed with daily oral risperidone, which confirms the consistency of the drug’s PK behavior. This result reinforces the potential for effective transition between these treatment modalities, providing clinicians with a viable option for patients who may struggle with adherence to daily oral regimens [26]. In addition, this result is also supported by a Phase 1 population PK model where a sequential parent metabolite model was used to simulate TV-46000 TAM concentrations for different dosing regimens. This modeling study showed that TV-46000 dose strengths for both q1m (50 mg, 75 mg, 100 mg, or 125 mg) and q2m (100 mg, 150 mg, 200 mg, or 250 mg) provide adequate TAM exposure at both dosing schedules, with comparable exposure to that of 2- to 5-mg daily oral risperidone [27]. TV-46000 exhibits unique characteristics compared with other LAI formulations of risperidone, such as its innovative copolymer-based drug delivery technology allowing SC administration and sustained-release properties [28]. Because of the sustained-release PK profile, dose proportionality, and comparability to oral risperidone, TV-46000 eliminates the need for oral supplementation during initiation, addressing a common barrier to treatment adherence seen with traditional antipsychotic therapies [23]. The ability to maintain therapeutic levels and the ability of the health care professional to closely monitor treatment adherence could significantly improve patient outcomes by reducing relapse rates and hospitalizations associated with nonadherence. The flexibility of TV-46000 also extends to injection-site interchangeability without compromising the therapeutic efficacy of the drug. An exploratory assessment of the impact of injection site (abdomen vs back of the upper arm) was conducted in this study. This comparison was based on single-dose data without formal statistical testing. For the 225-mg dose, systemic exposure was approximately 30% higher when the injection was administered in the back of the upper arm than in the abdomen. However, exposure ranges overlapped, and findings should be interpreted in the context of interparticipant variability. Of note, post hoc analyses from Phase 3 randomized controlled trials of TV-46000 had a favorable benefit–risk profile regardless of which injection site was used [29, 30]. Safety and local tolerability assessments demonstrated that TV-46000 was generally well tolerated across all dose levels. The systemic safety profile aligned with expectations of risperidone pharmacology. Adverse events primarily consisted of mild to moderate injection-site reactions, weight gain, and transient increases in blood creatine phosphokinase levels. Importantly, only two SAEs were reported: one completed suicide and one exacerbation of schizophrenia, neither of which was deemed related to TV-46000 or oral risperidone by investigators. Phase 3 clinical trials of TV-46000 have found similar safety results, with most AEs reported to be mild or moderate, particularly injection-site reactions and injection-site pain. This was consistent across both q1m and q2m formulations [31, 32]. Although the study includes methodological limitations, its findings contribute meaningfully to the evidence base. As a Phase 1, open-label trial, the sample size was limited and the study was not designed to assess efficacy outcomes or to perform formal statistical comparisons between dose groups. The assessment of the impact of injection site (abdomen vs back of the upper arm) was exploratory and based on single-dose data. In addition, this Phase 1 study included an oral risperidone run-in and washout period and was not designed to evaluate PK exposure during switching from other antipsychotic treatments. Population PK-based analyses informing dosing considerations when switching to TV-46000 from other LAIs have been reported elsewhere [33–35]. These limitations should be considered when interpreting the results. Conclusions This study has shown that TV-46000 demonstrates a favorable PK and safety profile with rapid absorption, predictable systemic exposure, optimal peak-to-trough fluctuations, and sustained systemic concentrations of TV-46000. The prolonged half-life and consistent plasma concentrations underscore the innovative drug delivery technology of TV-46000, which ensures controlled risperidone release over time. These attributes of TV-46000 can improve long-term outcomes and quality of life for individuals living with schizophrenia. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 344 KB) Supplementary file1 (PDF 344 KB)